World News: 12:00 GMT Wednesday 11th September 2019. [SINTX Technologies, Inc. via Globe Newswire via SPi World News]
SALT LAKE CITY, UT, Sept. 11, 2019 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (the “Company”), an OEM ceramics company that develops and commercializes silicon nitride for medical and non-medical applications, today announced that it has retained Ascendiant Capital Markets, LLC of Irvine, California, Member FINRA & SIPC (“Ascendiant Capital”), as investment bank and advisor, to identify strategic opportunities in the dental space.
“While we have been working closely with dental implant companies in specific development projects, Ascendiant Capital will play a critical role in disseminating our R&D advancements to a wider audience of partners, and helping commercialize the technology,” stated Dr. Sonny Bal, President and CEO of SINTX. “We are excited to represent SINTX Technologies, having deep experience and knowledge of dental companies worldwide,” said Dr. Christopher Gayde, a former practicing dentist and Managing Director of Ascendiant Capital’s Dental Investment Banking Group.
Over the last nine months, SINTX has made further advancements in its portfolio of dental technologies, beyond the manufacturing and development of dental implants made from its silicon nitride. The marked expansion in opportunity – which is backed up by successful testing – encouraged SINTX to engage Ascendiant Capital to pursue a wide range of potential partnerships.
The new technologies include extensive work on zirconia dental implants, and the 3-D laser surface functionalization of both titanium metal, and zirconia ceramics used to make modern dental implants. “With these new technologies, all of the desirable attributes of silicon nitride can be applied to other, proven materials that are used to make structural dental implants. The two key properties that differentiate silicon nitride are surface resistance to oral bacteria, and enhanced biologic fixation to bone; both of which have been corroborated by testing done at SINTX, and by multiple, independent outside partners,” said Dr. Bal.
SINTX Technologies is an OEM ceramics company that develops and commercializes silicon nitride for medical and non-medical applications. The core strength of SINTX Technologies is the manufacturing, research, and development of silicon nitride ceramics for external partners. The Company presently manufactures silicon nitride spinal implants in its ISO 13485 certified manufacturing facility for CTL-Amedica, the exclusive retail channel for silicon nitride spinal implants.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (“PSLRA”) that are subject to a number of risks and uncertainties. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. There can be no assurance that any of the anticipated results will occur on a timely basis or at all due to certain risks and uncertainties, a discussion of which can be found in SINTX’s Risk Factors disclosure in its Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 11, 2019, and in SINTX’s other filings with the SEC. SINTX disclaims any obligation to update any forward-looking statements. SINTX undertakes no obligation to publicly revise or update the forward-looking statements to reflect events or circumstances that arise after the date of this report.
Contact:SINTX Technologies 801.839.3502IR@sintx.com
Globe Newswire: 12:00 GMT Wednesday 11th September 2019
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.